L. Manirakiza, Victoria Nambasa, S. Nanyonga, Allan Serwanga, M. Alphonsus, Nankola Denis, H. Ndagije
Introduction: Ceftriaxone is a third generation cephalosporin recommended as first line treatment option for a number of diseases in Uganda. However, the National Drug Authority has in the recent past received complaints of suspected treatment failure from clinicians who use different brands of ceftriaxone in Uganda. The main aim of the study was to document the treatment outcome following use of ceftriaxone and evaluating the use of ceftriaxone against the current treatment guidelines in Uganda. Methods: A descriptive observational, non-intervention study design to document treatment outcomes after administration of Ceftriaxone injection in hospitalized patients was undertaken in Mubende. A total of 100 hospitalized patients treated with ceftriaxone were enrolled. Results: Overall, Ceftriaxone was used to treat pneumonia in the paediatric ward, presumptive therapy for infection following caesarean section (n=47) and PID in the post-natal ward, while on surgical and medical wards, Ceftriaxone was used to manage upper respiratory infection, bacterial infections and meningitis. There were no Adverse Events reported to have occurred during treatment with ceftriaxone. Of the patients treated with ceftriaxone 18% completed their doses and had regular administration. Majority 60% of the patients had irregular administration with completed doses and 22% did not complete their doses. Conclusion: There is low treatment outcome during use of Ceftriaxone and the empirically treatment is highly prevalent in the hospital. There is high number of inappropriate drug administration, in which patients usually miss doses or do not complete as prescribed. This practice has an effect of affecting the patient outcomes and aggravating antimicrobial resistance. Choice of ceftriaxone use is not guided by culture and sensitivity due to lack of inadequate laboratory infrastructure.
{"title":"Drug Use Evaluation (DUE) of Ceftriaxone in Mubende Regional Referral Hospital, Uganda: A Cross-Sectional Survey","authors":"L. Manirakiza, Victoria Nambasa, S. Nanyonga, Allan Serwanga, M. Alphonsus, Nankola Denis, H. Ndagije","doi":"10.26502/jppr.0024","DOIUrl":"https://doi.org/10.26502/jppr.0024","url":null,"abstract":"Introduction: Ceftriaxone is a third generation cephalosporin recommended as first line treatment option for a number of diseases in Uganda. However, the National Drug Authority has in the recent past received complaints of suspected treatment failure from clinicians who use different brands of ceftriaxone in Uganda. The main aim of the study was to document the treatment outcome following use of ceftriaxone and evaluating the use of ceftriaxone against the current treatment guidelines in Uganda. Methods: A descriptive observational, non-intervention study design to document treatment outcomes after administration of Ceftriaxone injection in hospitalized patients was undertaken in Mubende. A total of 100 hospitalized patients treated with ceftriaxone were enrolled. Results: Overall, Ceftriaxone was used to treat pneumonia in the paediatric ward, presumptive therapy for infection following caesarean section (n=47) and PID in the post-natal ward, while on surgical and medical wards, Ceftriaxone was used to manage upper respiratory infection, bacterial infections and meningitis. There were no Adverse Events reported to have occurred during treatment with ceftriaxone. Of the patients treated with ceftriaxone 18% completed their doses and had regular administration. Majority 60% of the patients had irregular administration with completed doses and 22% did not complete their doses. Conclusion: There is low treatment outcome during use of Ceftriaxone and the empirically treatment is highly prevalent in the hospital. There is high number of inappropriate drug administration, in which patients usually miss doses or do not complete as prescribed. This practice has an effect of affecting the patient outcomes and aggravating antimicrobial resistance. Choice of ceftriaxone use is not guided by culture and sensitivity due to lack of inadequate laboratory infrastructure.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69351732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Gažová, M. Kolesárová, M. Orinak, D. Kolesár, J. Kyselovič
Objective: Pain is a part of every human life and typically, example is a chronic pain in tumour diseases. In therapy of the chronic cancer pain, opioid analgesics have irreplaceable role. Methods: This retrospective analysis was conducted from January 2015 to March 2015 using the prescriptions of strong opioid analgesics accepted by pharmacy VITAE. Prescriptions of strong analgesics were written in the Oncology Institute in Kosice to adult patients. Opioid prescriptions for all patients in analyses had cancer medical diagnosis. Characterization of patients, diagnosis of cancer type, characterization of prescribed opioids analgesics – generic name and rug forms of prescribed medicament were analyzed in retrospective analyses of the prescriptions. Results: In total, there were 332 prescriptions (100 % of cancer) of strong opioids for 151 (54% male; 46% female) patients treated in the East-Slovak Oncology Institute in Kosice, Slovakia, during the study period. The youngest patient - woman was 27 and the oldest patient - woman was 88. The most frequent cancer diagnosis were the carcinoma of respiratory and thorax organs (male) and the carcinoma of breast (female). The number of package of strong opioids was 543 (fentanyl (44%), buprenorphine (26%), oxycodone (12%), tapentanol (10%), morphine (7%) and hydromorphone (1%)). Conclusions: Our analysis demonstrated, that despite the fact that morphine is still considered as a gold standard in the oncologic pain therapy, other opioids are more frequently prescribed as fentanyl, buprenorphine, oxycodone or new molecule tapentadol. All substances were prescribed for intense pain emerged from different type of advanced tumour diseases.
{"title":"Prescriptions of Strong Opioid Analgesics in Primary Care (Pharmacy Care)","authors":"A. Gažová, M. Kolesárová, M. Orinak, D. Kolesár, J. Kyselovič","doi":"10.26502/JPPR.0014","DOIUrl":"https://doi.org/10.26502/JPPR.0014","url":null,"abstract":"Objective: Pain is a part of every human life and typically, example is a chronic pain in tumour diseases. In therapy of the chronic cancer pain, opioid analgesics have irreplaceable role. Methods: This retrospective analysis was conducted from January 2015 to March 2015 using the prescriptions of strong opioid analgesics accepted by pharmacy VITAE. Prescriptions of strong analgesics were written in the Oncology Institute in Kosice to adult patients. Opioid prescriptions for all patients in analyses had cancer medical diagnosis. Characterization of patients, diagnosis of cancer type, characterization of prescribed opioids analgesics – generic name and rug forms of prescribed medicament were analyzed in retrospective analyses of the prescriptions. Results: In total, there were 332 prescriptions (100 % of cancer) of strong opioids for 151 (54% male; 46% female) patients treated in the East-Slovak Oncology Institute in Kosice, Slovakia, during the study period. The youngest patient - woman was 27 and the oldest patient - woman was 88. The most frequent cancer diagnosis were the carcinoma of respiratory and thorax organs (male) and the carcinoma of breast (female). The number of package of strong opioids was 543 (fentanyl (44%), buprenorphine (26%), oxycodone (12%), tapentanol (10%), morphine (7%) and hydromorphone (1%)). Conclusions: Our analysis demonstrated, that despite the fact that morphine is still considered as a gold standard in the oncologic pain therapy, other opioids are more frequently prescribed as fentanyl, buprenorphine, oxycodone or new molecule tapentadol. All substances were prescribed for intense pain emerged from different type of advanced tumour diseases.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69351326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular interaction of pharmaceutical residual solvents mixture (2-Butanol with m-Xylene) were studied through deep investigation on thermodynamic properties (Enthalpy, Entropy, Free energy) over the entire range of composition at temperature of 298.15 K to 323.15 K and at atmospheric pressure. Results are interpreted and reported in the light of solvation process which is referred to as the transition of molecules from their own environment. Next, the excess thermodynamic properties were calculated, and these excess properties were fitted by the Redlich–Kister polynomial equation. The calculated excess properties are discussed in terms of molecular interactions between 2-Butanol and m-Xylene.
在298.15 K ~ 323.15 K和常压条件下，对药物残留溶剂(2-丁醇-间二甲苯)混合物在整个组成范围内的热力学性质(焓、熵、自由能)进行了深入研究。结果被解释和报告在溶剂化过程，这是指分子从自己的环境过渡。其次，计算了多余的热力学性质，并用Redlich-Kister多项式方程拟合了多余的热力学性质。从2-丁醇与间二甲苯分子相互作用的角度讨论了计算得到的过量性质。
{"title":"Binary Mixture of Pharmaceutical Residual Solvents and Their Thermodynamic Investigation","authors":"M. Rahman, M. Habibullah","doi":"10.26502/fjppr.052","DOIUrl":"https://doi.org/10.26502/fjppr.052","url":null,"abstract":"Molecular interaction of pharmaceutical residual solvents mixture (2-Butanol with m-Xylene) were studied through deep investigation on thermodynamic properties (Enthalpy, Entropy, Free energy) over the entire range of composition at temperature of 298.15 K to 323.15 K and at atmospheric pressure. Results are interpreted and reported in the light of solvation process which is referred to as the transition of molecules from their own environment. Next, the excess thermodynamic properties were calculated, and these excess properties were fitted by the Redlich–Kister polynomial equation. The calculated excess properties are discussed in terms of molecular interactions between 2-Butanol and m-Xylene.","PeriodicalId":73897,"journal":{"name":"Journal of pharmacy and pharmacology research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：